Fig. 4

Targeting B7-H4 counteracted the DOX-induced chemo-resistance and increased the sensitivity to DOX, paclitaxel or carboplatin in TNBC cells. To examine the effect of B7-H4 activation on cell viability of MDA-MB-435/WT and MDA-MB-435/DOX cells, different concentrations of anti-B7-H4 antibody were treated for 24 (a), 48 (b) and 72 h (c). Cell proliferation was determined by CCK-8 assay. The combination treatment of mAb MIH43 and paclitaxel (d), carboplatin (e) or DOX (f) increased the cell growth inhibition rate in both MDA-MB-435/WT and MDA-MB-435/DOX cells. Columns, mean of 3 independent experiments done in triplicates, *p < 0.05